Matteo Carlino
马泰奥·卡利诺
MBBS, PhD, FRACP
Senior Staff Specialist Medical Oncologist; Associate Professor高级医学肿瘤学家；副教授
👥Biography 个人简介
Matteo Carlino is a leading melanoma oncologist at Westmead Hospital, Sydney, specialising in neoadjuvant immunotherapy and mechanisms of immune checkpoint resistance. He has been a key investigator in NEOMAPPP and KEYNOTE-716, advancing neoadjuvant pembrolizumab for resectable stage III melanoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Neoadjuvant Immunotherapy
Key investigator in NEOMAPPP and KEYNOTE-716 trials, demonstrating that neoadjuvant pembrolizumab achieves high pathological complete response rates and improves event-free survival.
Resistance Mechanisms
Pioneered research identifying genomic and transcriptomic drivers of primary and acquired PD-1 resistance in melanoma, guiding next-generation combination strategies.
Representative Works 代表性著作
Neoadjuvant Pembrolizumab or Placebo plus Surgery and Adjuvant Pembrolizumab in Resectable Stage III Melanoma (KEYNOTE-716)
The Lancet Oncology (2023)
Demonstrated neoadjuvant pembrolizumab significantly improves pathological complete response and event-free survival in resectable stage III melanoma.
Resistance Mechanisms to Anti-PD-1 Checkpoint Blockade in High-Risk Resected Melanoma
Nature Medicine (2022)
Identified genomic and immune signatures predictive of pembrolizumab resistance, providing a framework for overcoming immune checkpoint failure.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 马泰奥·卡利诺 的研究动态
Follow Matteo Carlino's research updates
留下邮箱，当我们发布与 Matteo Carlino（Westmead Hospital / Blacktown Hospital, University of Sydney）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment